Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 10, 1999, Pages 2417-2422

  Snydman, D R ^a   Jacobus, N V ^a   McDermott, L A ^a   Supran, S ^a   Cuchural Jr , G J ^a   Finegold, S ^b   Harrell, L ^c   Hecht, D W ^d   Iannini, P ^e   Jenkins, S ^f   Pierson, Carl ^g   Rihs, J ^b   Gorbach, S L ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^e DANBURY HOSPITAL   (United States)

^f UNIVERSITY OF FLORIDA   (United States)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFMETAZOLE; CEFOTETAN; CEFTIZOXIME; CHLORAMPHENICOL; CLINDAMYCIN; IMIPENEM; METRONIDAZOLE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TICARCILLIN; TIMENTIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLASMID; PRIORITY JOURNAL;

EID: 0032843496     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.10.2417     Document Type: Article

References (27)

1. Cornick, N. A., G. J. Cuchural, D. R. Snydman, N. V. Jacobus, P. Iannini, G. Hill, T. Cleary, J. P. O'Keefe, C. Person, and S. M. Finegold. 1990. The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987. J. Antimicrob. Chemother. 25:1011-1019.
2. Cuchural, G. J., F. P. Tally, N. V. Jacobus, S. L. Gorbach, K. Aldridge, T. Cleary, S, M. Finegold, G. Hill, P. Iannini, J. P. O'Keefe, and C. Pierson. 1984. Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: comparison of 1981 with 1982. Antimicrob. Agents Chemother. 26:145-148.
3. Cuchural, G. J., M. H. Malamy, and F. P. Tally. 1986. β-Lactamase-mediated imipenem resistance in Bacteroides fragilis. Antimicrob. Agents Chemother. 30:645-648.
4. Cuchural, G. J., F. P. Tally, N. V. Jacobus, K. Aldridge, T. Cleary, S. M. Finegold, G. Hill, P. Iannini, J. P. O'Keefe, and C. Pierson. 1988. Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation. Antimicrob. Agents Chemother. 32:717-722.
5. Cuchural, G. J., F. P. Tally, N. V. Jacobus, T. Cleary, S. M. Finegold, G. Hill, P. Iannini, J. P. O'Keefe, and C. Pierson. 1990. Comparative activities of new β-lactam agents against members of the Bacteroides fragilis group. Antimicrob. Agents Chemother. 34:479-480.
6. Gorbach, S. L., and J. G. Bartlett. 1974. Anaerobic infections. N. Engl. J. Med. 290:1177-1184, 1237-1245.
7. Holdemann, L. V., E. P. Cato, and W. E. Moore. 1977. Anaerobic laboratory manual, 4th ed. Virginia Polytechnic Institute, Blacksburg, Va.
8. Hurlbut, S., G. J. Cuchural, and F. P. Tally. 1990. Bacteroides distasonis mediated by a novel β-lactamase. Antimicrob. Agents Chemother. 30:117-120.
9. Jacobus, N. V., G. J. Cuchural, and F. P. Tally. 1989. In-vitro susceptibility of the Bacteroides fragilis group and the inoculum effect of newer β-lactam antibiotics on this group of organisms. J. Antimicrob. Chemother. 24:675-682.
10. National Committee for Clinical Laboratory Standards. 1997. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 4th ed., vol. 13. Approved standard M11-A4. National Committee for Clinical Laboratory Standards, Villanova, Pa.
11. Nguyen, M. H., V. L. Yu, A. J. Morris, L. McDermott, M. W. Wagener, L. Harrell, and D. R. Snydman. Antimicrobial resistance and clinical outcome for Bacteroides bacteremia: results from a multicenter, prospective observational trial. Clin. Infect. Dis., in press.
12. Nichols, R. L., and J. W. Smith. 1993. Wound and intraabdominal infections: microbiological considerations and approaches to treatment. Clin. Infect. Dis. 16(Suppl. 4):S266-S272.
13. Piddock, L. V. J., and R. Wise. 1987. Cefoxitin resistance in Bacteroides species: evidence indicating two mechanisms causing decreased susceptibility. J. Antimicrob. Chemother. 19:161-170.
14. Rasmussen, B. A., Y. Gluzman, and F. P. Tally. 1990. Cloning and sequencing of the class b β-lactamase gene (ccrA ) from Bacteroides fragilis metallo-β-lactamase TAL3636. Antimicrob. Agents Chemother. 34:1590-1592.
15. Redondo, M. C., M. D. J. Arbo, J. Grindlinger, and D. R. Snydman. 1995. Attributable mortality of bacteremia associated with the Bacteroides fragilis group. Clin. Infect. Dis. 20:1492-1496.
16. Rasenblatt, J. E., and I. Brook. 1993. Clinical relevance of susceptibility testing of anaerobic bacteremia. Clin. Infect. Dis. 16(Suppl. 4):S446-S448.
17. Snydman, D. R., G. J. Cuchural, and The National Anaerobic Susceptibility Study Group. 1994. Susceptibility variations in Bacteroides fragilis: a national survey. Infect. Dis. Clin. Pract. 3(Suppl. 1):S34-S43.
18. Snydman, D. R., G. J. Cuchural, L. McDermott, and M. Gill. 1992. Correlation of various in-vitro testing methods with clinical outcomes in patients with Bacteroides fragilis group infections treated with cefoxitin: a retrospective analysis. Antimicrob. Agents Chemother. 36:540-544.
19. Snydman, D. R., L. McDermott, G. J. Cuchural, D. W. Hecht, P. B. Iannini, L. J. Harrell, S. G. Jenkins, J. P. O'Keefe, C. L. Pierson, J. D. Ribs, V. L. Yu, S. M. Finegold, and S. L. Gorbach. 1996. Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994. Clin. Infect. Dis. 23(Suppl. 1):S54-S65.
20. Snydman, D. R., and L. McDermott. 1996. Analysis of the in vitro activity of trovafloxacin (CP-99,219) against Bacteroides species. Infect. Dis. Clin. Pract. 5(Suppl. 3):S96-S100.
21. Summanen, P., E. J. Baron, D. M. Citron, C. A. Strong, H. Wexler, and S. M. Finegold. 1993. Wadsworth anaerobic bacteriology manual, 5th ed. Star Publishing, Belmont, Calif.
22. Tally, F. P., N. V. Jacobus, J. G. Bartlett, and S. L. Gorbach. 1975. Susceptibility of anaerobes to cefoxitin and other cephalosporins. Antimicrob. Agents Chemother. 7:128-132.
23. Tally, F. P., D. R. Snydman, S. L. Gorbach, and M. H. Malamy. 1979. Plasmid-mediated, transferable resistance to clindamycin and erythromycin in Bacteroides fragilis. J. Infect. Dis. 139:83-88.
24. Tally, F. P., G. J. Cuchural, N. V. Jacobus, S. L. Gorbach, K. Aldridge, T. Cleary, S. M. Finegold, G. Hill, P. Iannini, J. P. O'Keefe, and C. Pierson. 1983. Susceptibility of the Bacteroides fragilis group in the United States in 1981. Antimicrob. Agents Chemother. 23:536-540.
25. Tally, F. P., G. J. Cuchural, N. V. Jacobus, S. L. Gorbach, K. Aldridge, T. Cleary, S. M. Finegold, G. Hill, P. Iannini. J. P. O'Keefe, and C. Pierson. 1985. Nationwide study of the susceptibility of the Bacteroides fragilis group in the United States. Antimicrob. Agents Chemother. 28:675-677.
26. Wexler, H. M., and S. Halebian. 1990. Alterations to the penicillin-binding proteins in the Bacteroides fragilis group: a mechanism for non-β-lactamase mediated cefoxitin resistance. J. Antimicrob. Chemother. 26:7-20.
27. Yotsuji, A., S. Minami, M. Inoue, and S. Mitsuhashi. 1983. Properties of a novel β-lactamase produced by Bacteroides fragilis. Antimicrob. Agents Chemother. 24:925-929.